Mechanism of Action of Sacubitril/Valsartan (ARNI)
Sacubitril/valsartan works through dual mechanisms: sacubitril inhibits neprilysin (an enzyme that degrades beneficial natriuretic peptides), while valsartan blocks the angiotensin II type-1 receptor, simultaneously enhancing protective cardiovascular pathways and blocking harmful ones. 1
Dual Component Action
Sacubitril Component (Neprilysin Inhibition)
Sacubitril is a prodrug that is converted by esterases to its active metabolite LBQ657, which inhibits neprilysin (neutral endopeptidase; NEP) 1
Neprilysin normally degrades multiple vasoactive peptides, including:
By blocking neprilysin, sacubitril increases levels of these beneficial peptides, particularly natriuretic peptides, which produce:
Valsartan Component (Angiotensin Receptor Blockade)
- Valsartan selectively blocks the angiotensin II type-1 (AT1) receptor, preventing angiotensin II from exerting its harmful effects 1
- This blockade:
- Prevents vasoconstriction
- Inhibits angiotensin II-dependent aldosterone release
- Reduces cardiac remodeling
- Does not interfere with bradykinin metabolism (unlike ACE inhibitors), which is why the combination avoids the excessive angioedema risk seen with earlier neprilysin inhibitor combinations 3
Synergistic Cardiovascular Effects
The combination addresses two major pathophysiological mechanisms in heart failure simultaneously: activation of the renin-angiotensin-aldosterone system (blocked by valsartan) and decreased sensitivity to natriuretic peptides (enhanced by sacubitril) 2, 3, 1
Observable Pharmacodynamic Effects
When administered, sacubitril/valsartan produces:
- Increased plasma ANP levels (approximately 4-fold increase) 4
- Increased plasma BNP (a neprilysin substrate) 1
- Decreased NT-proBNP (not a neprilysin substrate, reflects improved cardiac function) 1
- Increased urinary cGMP (marker of natriuretic peptide activity) 1
- Decreased aldosterone and endothelin-1 1
- Increased plasma renin activity (evidence of AT1 receptor blockade) 1
Clinical Translation
The dual mechanism translates into superior clinical outcomes compared to ACE inhibitors or ARBs alone. In PARADIGM-HF, this mechanism produced a 20% reduction in cardiovascular death or heart failure hospitalization compared to enalapril 2, 3.
Important Caveat
Neprilysin is a non-selective enzyme with multiple biological targets, including involvement in amyloid-β clearance from the brain. Administration of sacubitril/valsartan increases CSF Aβ1-38 levels, though the clinical relevance remains unknown 1. This broad substrate profile explains both the pleiotropic benefits and the need for monitoring multiple systems.